Associations of High-Density Lipoprotein Cholesterol and Framingham Cardiovascular Risk in African Type 2 Diabetics with Diabetic Retinopathy

Author(s):  
Benjamin Longo-Mbenza ◽  
Moise Mvitu Muaka ◽  
Thierry Gombet ◽  
Igor Longo Phemba ◽  
Steve Cook ◽  
...  
Author(s):  
Smita V Patil ◽  
Anita P Mandare ◽  
Gaikwad B Pandurang

Objective: There are probably 100 million people in the world with diabetes mellitus (DM), and incidences of diabetes are on the rise. Dyslipidemia is one of the common disorders which are seen in most of the diabetes patients, which causes cardiovascular disorders. The aim of this study is to investigate the total cholesterol (TC), triacylglycerols (TGs), high-density lipoprotein cholesterol (HDL-C) in Type 2 DM, and healthy controls.Methods: The study was conducted on 50 controls and 50 Type 2 diabetic subjects between age group of 30 and 60 years. Serum TC was determined by an enzymatic (cholesterol oxidase/phenol-aminophenazone [PAP]) colorimetric method and TGs were determined by an enzymatic (glycerol phosphate oxidase-PAP) method, and HDL-C was estimated by a precipitant method. Statistical analysis was done using unpaired t-test.Results: The mean value of TC, TGs, and HDL-C in normal subjects is 165.5±24.24, 118.7±41.58, 28.38±7.85 mg/dl, respectively, and the value of TC, TGs, and HDL-C in diabetic patients is 179±31.69, 164.35±27.93, 25.4±6.86 mg/dl, respectively. The observed difference in the means of TC, TGs, and HDL-C in normal and diabetic are statistically significant (p<0.05).Conclusion: From the present study, it is concluded that TC, TGs, and HDL-C levels for all persons with Type 2 DM should be done as a routine test. Furthermore, early diagnosis and treatment of dyslipidemia can be used as a preventive measure for the development of cardiovascular disease in Type 2 diabetes.Keywords: Diabetes mellitus, Dyslipidemia, Lipid profile, Total cholesterol, Triglycerides, High-density lipoprotein cholesterol.


Angiology ◽  
2009 ◽  
Vol 60 (5) ◽  
pp. 644-649 ◽  
Author(s):  
Thomas F. Whayne

High-density lipoproteins are regarded as “good guys” but not always. Situations involving high-density lipoproteins are discussed and medication results are considered. Clinicians usually consider high-density lipoprotein cholesterol. Nicotinic acid is the best available medication to elevate high-density lipoprotein cholesterol and this appears beneficial for cardiovascular risk. The major problem with nicotinic acid is that many patients do not tolerate the associated flushing. Laropiprant decreases this flushing and has an approval in Europe but not in the United States. The most potent medications for increasing high-density lipoprotein cholesterol are cholesteryl ester transfer protein inhibitors. The initial drug in this class, torcetrapib, was eliminated by excess cardiovascular problems. Two newer cholesteryl ester transfer protein inhibitors, R1658 and anacetrapib, initially appear promising. High-density lipoprotein cholesterol may play an important role in improving cardiovascular risk in the 60% of patients who do not receive cardiovascular mortality/morbidity benefit from low-density lipoproteins reduction by statins.


Sign in / Sign up

Export Citation Format

Share Document